Italian Researchers Validate CastPCR as Companion to TKI Treatment for BRAF Mutated Melanoma | GenomeWeb

NEW YORK (GenomeWeb) – Investigators at an Italian research hospital have demonstrated Thermo Fisher Scientific's competitive allele specific TaqMan PCR (castPCR) is a sensitive and specific method to detect BRAF mutations in melanoma.

Mutation testing can have an impact on treatment decisions for certain kinds of cancer drugs, and, in the case of BRAF gene mutations, status can predict treatment response to tyrosine kinase inhibitors (TKIs).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.